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The objective of this study was to analyze the variation in antimicrobials’ consumption and the costs 
related to their use at a University Hospital between 1999 and 2004. The annual consumption of nine 
antimicrobials, expressed in DDD/100 patients-day, and the direct costs with their acquisition were 
evaluated. Analysis of variance and regression techniques were used to compare data, considering a 
significance level of 5%. The most consumed antimicrobials were amikacin and ceftriaxone. In general, 
antimicrobials consumption, expressed in DDD/100 patients-day, increased from 9.21 in 1999 to 25.08 
in 2004 (p≤0.0001). When analyzing antimicrobial consumption as related to specific hospital units, the 
ICU showed the highest consumption followed by Chemotherapy and Medical Clinical units, respectively. 
In addition, the number of patients-day increased from 2671/month in 1999 to 3502/month in 2004, 
p≤0.0001. As a consequence, total expenditure with antimicrobials increased from R$ 98.89 per 100 
patients-day in 1999 to R$ 731.26 in 2004, p≤0.0001. Between 1999 and 2004 significant increases in 
both consumption and financial expenditure with antimicrobials were observed.
Uniterms: Medicines/Defined Daily Doses. Medicines/utilization. Antimicrobials/consumption 
Pharmacoepidemiology.
O trabalho teve por objetivo analisar a variação do consumo e gastos financeiros com antimicrobianos 
em Hospital Universitário entre 1999 e 2004. Analisou-se 9 antimicrobianos, sendo o consumo expresso 
em DDDs/100 pacientes-dia e o preço médio de compra obtido do relatório da farmácia hospitalar. 
As variações anuais no consumo, o consumo por tipo de unidades de internação e gastos com cada 
antimicrobiano foram estudadas por análise de variância. Adotou-se 5% como limiar de significância. 
Os antimicrobianos mais consumidos no período foram amicacina e ceftriaxona. Observou-se aumento 
no consumo dos antimicrobianos selecionados de 9,21 DDDs/100 pacientes-dia em 1999 para 25,08 em 
2004 (p≤0,0001). Entre as unidades de internação, a UTI apresentou o maior consumo médio, seguindo-se 
as unidades de Quimioterapia e Clínica Médica. A média mensal de pacientes-dia atendidos aumentou de 
2671 em 1999 para 3502 em 2004 (p≤0,0001). Observou-se aumento significativo nos gastos totais com 
antimicrobianos no período (R$ 98,89 x R$ 731,26 por 100 pacientes-dia entre 1999 e 2004, p≤0,0001). 
Observou-se aumento significativo tanto na utilização quanto no gasto financeiro por 100 pacientes-dia 
diretamente relacionado à aquisição dos antimicrobianos estudados. 
Unitermos: Medicamentos/Dose Diária Definida. Medicamentos/uso. Antimicrobianos/consumo. 
Farmacoepidemiologia.
INTRODUCTION
One of the main world preoccupations respecting 
to medications use is related with antimicrobial therapy 
(Castro et al., 2002). The irrational use of antimicrobial 
medications in hospital environments brings consequences 
not only in costs, but also problems related with increase 
in microorganisms’ resistance, fostering to superinfection, 
higher risk for side effects, and “covering” of infectious 
diseases (Borges Filho et al., 2005). 
With all changes in microorganisms resistance pro-
file, it is necessary the growing use of more and more po-
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werful antimicrobial medications, generating so a vicious 
cycle; besides other problems, such as cost and duration 
increase of hospital admissions, (Fernades, Fernandes, Ri-
beiro Filho, 2000; Gould, 2002). Currently, the conception 
of rational use of antimicrobial agents has been envisaged 
as a primordial strategy for the control of dissemination 
of antimicrobial resistance. The control of antimicrobial 
agents in hospitals presupposes the knowledge about the 
situation of these medications consumption, using an ade-
quate methodology and adopting uniform criteria for such 
a purpose, which should be derived from studies about 
these medications utilization (Laporte, Tognoni, 1993; 
Ena, 1997; López-Medrano et al., 2005).
Studies involving the use of antimicrobial agents in 
certain hospital areas could be utilized to determine stan-
dards and trends of use, connecting then such information 
to antimicrobial resistance (Loeffler et al., 2003). The 
rational use of medicines could be defined as the employ-
ment of the adequate medication, with assured quality, 
in the lower therapeutic dose as possible, minimizing so 
the occurrence of adverse effects and maximizing the be-
neficial effects, with the lower cost as possible (Laporte, 
Tognoni, Rosenfeld, 1989). A program of supervision of 
antimicrobial agents use is essential in hospitals, in order 
to improve the prescription of antimicrobial agents and 
decrease hospital costs.
The pharmacoepidemiological analysis allows to 
quantify the current use of a selected medicine, outline its 
use profile respecting to time, determine if its respective 
utilization habits correspond to current status of knowled-
ge, identify possible reasons contributing for its consump-
tion oscillations, and give support to implementation of 
measures favoring the adequate utilization of medicines 
(Lee, Bergman, 1994).
The Defined Daily Dose (DDD) is a technical mea-
surement that standardizes the actual consumption of me-
dicines, based on the drug’s average daily dose for its main 
adult indication, in a period of 24 hours (Capellã, Laporte, 
1994). The purpose of this present work is to analyze the 
utilized antimicrobial agents at the University Hospital 
of Western Paraná (Hospital Universitário do Oeste do 
Paraná – HUOP) and in some of its admission units, as 
well as analyze the actual expenses with the consumption 
of these drugs, in the period of 1999 to 2004.
METHODS
The study was developed in the University Hospital 
of Cascavel linked to State University of Western Paraná 
(Universidade Estadual do Oeste do Paraná – UNIOES-
TE), in the period of 1999 January to 2004 December. It is 
a public hospital with approximately 150 beds, distributed 
in admission units of diverse specialties such as general 
practice, medical clinic, surgical and pediatrics, gynecolo-
gic and obstetric, oncologic, intensive care units (clinical 
and surgical), first aid and other areas of attendance.
This is a retrospective study, based on consumption 
records of selected antimicrobial agents, prescribed for 
the adult patients’ population of HUOP, which has uti-
lized the DDD to normalize the information referring to 
antimicrobial agents’ consumption in different hospital 
units and different years of study. The consumption data 
referring to hospital as a whole were analyzed, as well as 
the consumption data specific for some admission units. 
Infirmaries of several medical specialties were in-
cluded in the study, being that some of them were grouped 
and others were studied separately. Between the hospital 
units grouped for this study, the units of medical clinic, 
temporary attendance and general practice were jointly 
named as “medical clinic”, due to similar characteristics 
in the patients admitted by these units, for diverse clinical 
treatments. The group composed by the gynecologic and 
obstetric clinic, in conjunction with the obstetric center, 
was named “obstetric clinic”. The intensive care unit, 
chemotherapy unit and surgical clinic were studied sepa-
rately. The units of orthopedic and neurologic clinic, first 
aid and surgical center were excluded from the study, due 
to inconsistence of data related to number of patients-day 
and consumption of antimicrobial agents.
For this study, nine antimicrobial agents were selec-
ted; the majority of them being subjected to control by the 
Commission of Control of Hospital Infection (Comissão 
de Controle de Infecção Hospitalar – CCIH) and the re-
maining ones, clearly presenting great consumption in the 
hospital. The control of antimicrobial agents is developed 
by the Service of Control of Hospital Infection (Serviço de 
Controle de Infecção Hospitalar – SCIH) and the Service 
of Hospital Pharmacy, through a releasing card for antimi-
crobial agents of restrict use. The selected antimicrobial 
agents were: amikacin, cefotaxime, ceftazidime, ceftria-
xone, ciprofloxacin, clindamycin, imipenem/cilastatin, 
oxacillin and vancomycin.
 The quantity of utilized flasks of every analyzed 
antimicrobial agent was provided by the HUOP pharmacy, 
through electronic reports of monthly consumption issued 
by the program of stock control of the service of hospital 
pharmacy; and these reports were issued for the hospital 
as a whole, as well as for every selected admission unit. 
The quantities provided were converted into grams of 
every antimicrobial agent, according to their respective 
commercial presentations consumed. The data referring 
to the number of occupied beds and the rate of yearly beds 
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occupation were obtained from the hospital Service of 
Medical File and Statistics (Serviço de Arquivo Médico e 
Estatística – SAME).
The analysis of consumption of antimicrobial agents 
was developed utilizing the DDD, normalized for 100 
patients-day, as a reference measurement. The values of 
DDD for every antimicrobial agent were adapted from 
the table utilized by Monnet and Sorensen (1999). After 
the conversion from the consumption in grams to every 
antimicrobial agent DDD, it was calculated the number of 
DDDs normalized for 100 patients-day for every antimi-
crobial agent and month along the study period, utilizing 
the following formula (Lawton et al., 1999; Hidalgo, 
2006):
Where the number of patients-days was obtained 
from the relation
Number of Patients - day = O x N x T,
with: O = specific rate of beds occupation of the service; 
N = number of available beds; T = time period in days.
So defined, the number of DDDs per 100 patients-
day was utilized in this study to analyze the consumption 
variation in the selected antimicrobial agents.
To evaluate the financial costs referring to antimi-
crobial agents consumption in the hospital as a whole, it 
was utilized the purchase price contained in the report of 
consumption of medications from the program of stock 
control of hospital pharmacy.
The consumed quantity of every analyzed antimicro-
bial agent, in grams, jointly with the number of patients-
day, were stored in an electronic worksheet utilizing the 
software Excel® 5.0, to calculate the number of DDDs/100 
patients-day. The statistical analyses were developed utili-
zing the statistical package Statistica® 4.5, for Windows®. 
The monthly averages of both, DDDs/100 patients-day 
and every year number of patients-day, were compared by 
variance analysis (ANOVA). The temporal variation trend 
of variables of interest was analyzed by linear regression, 
being adopted as significance limit, in both cases, a £ 0.05. 
RESULTS
Table I presents the monthly average of the num-
ber of patients-day admitted at HUOP during every year 
of study period, as well as the yearly total of attended 
patients-day, with exception of pediatric units beds, be-
cause it is not possible to define the Defined Daily Dose 
for pediatric patients, once the drug daily posology is a 
function of patient’s weight.
During the period of 1999 to 2004, it was observed 
an increase of approximately 30% in the monthly average 
and yearly total of attended patients-day (p≤0.0001), but 
the yearly average of staying rate was stable in the studied 
period.
To quantify the general consumption of selected 
antimicrobial agents at HUOP, the monthly averages of 
DDDs/100 patients-day were calculated for every selected 
antimicrobial agent for year of study (Table II).
The most consumed antimicrobial agents at HUOP, 
in the period of this study, were amikacin and ceftriaxone. 
Besides, it is possible to observe a gradual increase in 
the consumption of several antimicrobial agents, such as 
ceftriaxone, ceftazidime, ciprofloxacin, clindamycin and 
imipenem (Table II). In the same period, amikacin has sho-
wn increase in consumption until the year of 2001, when 
the higher DDDs/100 patients-day (8.98) occurred; then, 
the DDDs/100 patients-day has fallen to approximately 6.5 
and maintained stability in the following years.
Respecting to imipenem/cilastatin, the higher con-
sumption was observed in the year of 2004, with monthly 
average of 1.26 DDDs/100 patients-day.
TABLE I – Number of attended patients-day and yearly average of staying at University Hospital of Western Paraná
Year Average of patients-day/month Total of patients-day/year Time of staying (days)
1999 2671 32052 4.67
2000 2741 32892 4.48
2001 2750 33000 4.70
2002 3341 40092 4.82
2003 3645 43740 4.76
2004 3502 42024 4.88
P ≤ 0.0001 0.5239
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The oxacillin, which was between the most utilized 
antimicrobial agents at study starting, presented relatively 
constant consumption along the study period, except for 
the year of 2002, justifying so the difference observed in 
the consumption of this antimicrobial agent in the period 
(p=0.0007), but without trend for defined increase or de-
crease. The vancomycin maintained a similar consumption 
standard in the years of 1999, 2000 and 2002. However, 
it is possible to observe an important increase in the 
DDDs/100 patients-day in the years of 2001, 2003 and 
2004. On the other hand, the consumption of cefotaxime 
was maintained constant.
Figure 1 presents the temporal evolution of total 
consumption of studied antimicrobial agents at HUOP, 
grouped per attending units as defined previously. Such 
procedure has enabled a better visualization of the varia-
tion in the global consumption of antimicrobial agents, in 
every attending unit of HUOP.
TABLE II – Variation in the average monthly consumption in DDDs/100 patients-day of nine analyzed antimicrobial agents at 
HUOP, in the period of 1999 to 2004
Antimicrobial agents 1999 2000 2001 2002 2003 2004 p*
Amikacin 3.45 4.88 8.98 6.85 6.28 6.63 0.0021
Cefotaxime 0.04 0.05 0.04 0.29 0.09 0.35 0.1024
Ceftazidime - - 0.18 0.33 1.19 1.35 0.0209
Ceftriaxone 2.57 3.15 5.20 6.23 7.27 8.32 ≤0.0001
Ciprofloxacin - - - 0.55 0.65 1.56 ≤0.0001
Clindamycin - - 0.92 1.27 1.93 2.67 0.0041
Imipenem/Cilastatin 0.32 0.37 0.57 0.43 0.51 1.26 ≤0.0001
Oxacillin 2.27 1.39 1.94 3.96 1.99 1.44 0.0007
Vancomycin 0.56 0.53 1.42 0.62 0.93 1.50 0.0326
TOTAL 9.21 10.37 19.25 20.53 20.84 25.08 0.0436
* ANOVA: comparison of monthly averages of consumption, expressed in DDD/100 patients-day, for every analyzed antimicrobial 
agents and year.
FIGURE 1 – Monthly average of total consumption of selected antimicrobial agents (expressed in DDDs/100 patients-day) utilized 
per admission unit of HUOP, in the study period.
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It is observed an increase in the monthly average 
consumption of selected antimicrobial agents, expressed 
in DDDs/100 patients-day, along the 6 years of study in 
all hospital units, except for Obstetric and Surgical units 
(Figure 1). The analysis of variance in the consumption 
of antimicrobial agents, taking into account the factors 
time and admission unit, has demonstrated significant 
difference between the units and along the time (ANOVA, 
p<0.0001 for both factors).
The Intensive Care Unit has presented the higher 
monthly average consumption of selected antimicrobial 
agents and also the higher consumption increase along the 
time, without trend to stabilization yet.
For the remaining attending units, the consumption 
variation of antimicrobial agents in the study period is less 
marked. The Chemotherapy and Medical units presented 
very similar behavior respecting to antimicrobial agents 
consumption, with important increase until 2002, but a 
trend to stabilization in 2003 and 2004. The consumption 
of antimicrobial agents in the surgical and obstetric units 
varied a little, along the study.
For the calculation of financial impact, it was utili-
zed a non linear regression analysis. Figure 2 demonstrates 
the yearly values, in reais (R$), spent with the 9 selected 
antimicrobial agents, utilizing for the calculation the ave-
rage purchase price of every flask of antimicrobial agent, 
in the studied period.
The Figure 2 illustrated a yearly variation of global 
expenditure with antimicrobial agents per 100 patients-
day, verified at HUOP in the studied period. It is observed 
an increase in the direct expenditures with antimicrobial 
agents, which is approximately linear between the years 
of 1999 and 2003, corresponding to an increase in the 
consumed quantity, expressed in DDD/100 patients-day, 
and an increase in the quantity of attended patients-day at 
HUOP, in the period. However, the increase of expenditu-
res with antimicrobial agents verified in 2004, respecting 
to remaining years, could not be explained in such a way, 
because the total expenditure was larger than the double of 
which would be expected, taking into account the verified 
increase in the global consumption of antimicrobial agents 
in DDD/100 patients-day weighed by the increase in the 
attendances volume (in patients-day) verified in the period. 
We did not find a plausible justification for this increase.
DISCUSSION
The excessive use of antimicrobial agents and the 
low adherence to measures for infection control have been 
identified as important factors for the increase of micro-
bial resistance in the hospital environment. Studies have 
demonstrated the utilization of antimicrobial agents in 
approximately 50% of admitted patients, which amounts 
almost 50% of hospital pharmacy budget; but with these 
antimicrobial treatments being inadequately utilized in 
30%-70% of times, due to incorrect choice of drug, dose 
or treatment duration (Murthy, 2001; Shankar et al. 2003; 
Cook, 2004; López-Medrano, 2005).
In the individual analysis of antimicrobial agents 
utilized at HUOP in the period of this study, the most 
consumed were amikacin and ceftriaxone. The ceftriaxone 
consumption has increased from 2.57 DDDs/100 patients-
day in the year of 1999 to 8.32 DDDs/100 patients-day in 
the year of 2004, as observed at Table II. Similar results 
were found by Hidalgo (2003), with the cephalosporin 
group representing the antimicrobial agents of higher 
consumption at the São Paulo Hospital, in São Paulo, 
Brazil; with ceftriaxone standing out within this group. 
Borges et al. (2005) have also verified that ceftriaxone 
was the cephalosporin of higher consumption in 2005 at 
the Municipal Hospital of Contagem, Minas Gerais, Brazil 
(8.3 DDDs/100 beds-day).
The ceftazidime and clindamycin (Table II) pre-
sented, from the year of 2001, a constant increase in 
consumption. The same antimicrobial agents analyzed 
by Nájera et al. (2003) in a general hospital in Spain, 
presented a different behavior from the one found in our 
study. These authors verified that these two antimicrobial 
agents did not follow a trend for consumption increase 
in the period of 1996 to 2000. The ceftazidime presented 
higher consumption in the years of 1996 (0.812 DDD/ 
100 beds-day) and 1998 (0.726 DDD/100 beds-day), with 
fall in consumption in the years of 1997 (0.443 DDD/100 
beds-day) and 1999 (0.401 DDD/100 beds-day). Carling 
FIGURE 2 – Analysis of total yearly expenditure with the 
antimicrobial agents studied at HUOP, in the period of 1999 
to 2004.
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et al. (2003), in a prospective study developed in a school 
hospital in Boston, observed that the clindamycin con-
sumption maintained constant (2.25 DDD/100 patients-
day, varying from 1.72 to 2.65).
Respecting to ciprofloxacin, the unique quinolone 
included in this study, and whose use at HUOP has star-
ted in 2002, it was observed a continuous increase in the 
monthly average consumption in DDDs/100 patients-day 
(Table II). These results are similar to those found by 
Nájera et al. (2003), in which the consumption of this 
antimicrobial agent, as of parenteral as oral use, presented 
progressive increase in the period of 1996 to 2000. On the 
other hand, Cook et al. (2004), worried with the increase 
of microbial resistance in a tertiary school hospital in 
North Carolina (USA), implemented a multidisciplinary 
program for control of broad-spectrum antimicrobial 
agents, suggesting rationalization or the interruption in 
the use of antimicrobial agents. This intervention reduced 
the consumption of ciprofloxacin from 12.40 DDD/100 
patients-day in the year of 2000 to 8.93 in the year of 2001.
The consumption of imipenem/cilastatin at HUOP 
was higher in the year of 2004 (1.26 DDDs/100 patients-
day). Still in the study of Cook et al. (2004), the control 
program of antimicrobial agents caused a decrease in the 
consumption of imipenem/cilastatin from 1.12 DDD/100 
patients-day in 2000 to 0.43 in 2001 (p=0.01). Oliveira 
(2002) has also noticed a decrease in the imipenem con-
sumption in the University Hospital of Triângulo Mineiro, 
in Uberaba. This drop was attributed to the starting of the 
control program of use of antimicrobial agents implemen-
ted in the institution, in 1998.
Respecting to consumption of oxacillin, the marked 
increase in consumption of this antimicrobial agent in the 
year of 2002 (Table II) has drawn the attention. This in-
crease could be due to a restriction in use of vancomycin, 
which presented a high consumption in the year of 2001. 
This can be observed at Table II, where the vancomy-
cin presents consumption about 3 times higher in that 
year, as compared to years of 2000 and 2002. Hidalgo 
(2003) has also observed excessive use of vancomycin, 
in 2001, at São Paulo Hospital; which was attributed to 
high prevalence of oxacillin-resistant staphylococcus. 
Besides, it was observed in this institution the appearance 
of vancomycin-resistant enterococci and intermediate 
vancomycin-resistant staphylococci (VISA). 
The consumption of antimicrobial agents in ICUs 
is differentiated as compared with other admission units; 
this is due to clinical characteristics of these units’ patients, 
whom in their majority are under critical and immunode-
pressed conditions; the high complexity of therapeutic and 
diagnostic procedures developed over there; and selective 
pressure by the use of antimicrobial agents, contributing 
so for a higher frequency of resistant microorganisms 
(Murthy, 2001).
In this study, respecting the monthly average con-
sumption of antimicrobial agents expressed in DDDs/100 
patients-day in the admission units, the ICU has shown 
higher consumption, being followed by the units of Che-
motherapy and Medical Clinic (Figure 1).
Nájera et al. (2003) have evaluated the global con-
sumption of antimicrobial agents in all hospital sectors, 
and also such consumption at ICU, but analyzing it separa-
tely. During the 5 years of study, the total consumption of 
antimicrobial agents was of 59.469 DDDs/100 beds-day, 
but when analyzing separately the ICU consumption, it 
was of 176.162, that is, a specific consumption 3 times 
higher as compared to global consumption. These data are 
compatible with our findings (Figure 1).
The Chemotherapy Unit is an outsourced sector 
within HUOP, being administered by a philanthropic 
entity named Western Paraná Union of Combat to Cancer 
(União Oeste Paranaense de Combate ao Câncer – UO-
PECCAN). All patients with treatments for diverse types 
of neoplasias requiring hospital admission are forwarded 
for this sector at HUOP. Because it is an outsourced sector, 
the majority of medications utilized by its patients are 
purchased with resource from the entity itself. Medica-
tions from the HUOP hospital pharmacy were used only, 
when UOPECCAN had not such medicines available in 
its stock. Thus, some antimicrobial agents utilized in the 
Chemotherapy Unit were from HUOP pharmacy; being, 
therefore, object of this study. It is observed at Figure 1 
that the monthly average consumption of antimicrobial 
agents in this unit, in DDDs/100 patients-day, has presen-
ted a practically linear increase in the period between 1999 
and 2003. However, draws the attention the year of 2004, 
in which a decrease of antimicrobial agents consumption 
occurred, as compared to previous two years; supposedly, 
it was due to an increase in the acquisition of antimicrobial 
agents by the philanthropic entity itself, leading to a de-
crease in the utilization of these medicines by the HUOP 
hospital pharmacy.
The HUOP unit of medical clinic attends patients 
of diverse clinical pathologies, between them, patients 
immunosuppressed and bearing infectious syndromes. 
Due to complexity of these patients, it is expected a high 
consumption of broad-spectrum antimicrobial agents, 
corresponding to observed at Figure 1, which shows a 
consumption equivalent to that of chemotherapy unit.
When analyzing the general consumption of all 
selected antimicrobial agents for this study, it is possible 
to observe a very important increase in the normalized 
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consumption year after year, passing from 9.21 DDDs/100 
patients-day in 1999 to 25.08 in 2004, which represents an 
increase of almost 3 times in 6 years (p=0.0436, Table II). 
An increase in the antimicrobial agents consumption 
was also observed in a university hospital of Porto Alegre. 
The average consumption of antimicrobial agents has 
increase from 83.8 to 124.58 DDDs/100 beds-day in an 
interval of 6 years (Castro et al., 1999). On the other hand, 
a study developed by Hidalgo (2003) has shown consump-
tion stability of 14 antimicrobial agents in the analyzed 
period at São Paulo Hospital, which counts on an acting 
Commission of Rationalization of Use of Antimicrobial 
Agents, with more than a decade from its implementation.
According to Follador (2005), pharmacoeconomics 
is a tool to be added to rational use of medications. If me-
dications are utilized with precise indication, in the correct 
form, and following the better decision criteria between 
benefits and risks, a good dose of economy will be already 
being applied.
In this study, only the expenses referring to con-
sumption of antimicrobial agents at HUOP, in the studied 
period, were considered. The economic analysis obser-
ved, did not target the evaluation of cost-benefit, cost-
effectiveness, or even cost minimization. The economic 
factor served only to represent the financial impact with 
the consumption of nine selected antimicrobial agents in 
this institution (Figure 2).
It is important to emphasize the utilization of an 
average purchase price for the analyzed antimicrobial 
agents, coming from the consumption report of stock 
control provided by hospital pharmacy. In this way, some 
hypotheses could be raised to justify the great increase 
evidenced in the expenditure with antimicrobial agents, 
such as: irregularity in the launch of purchase price of 
these drugs; emergency purchases of antimicrobial agents 
without public tender, with the drugs being acquired from 
drugstores, favoring cost increases; increase in the con-
sumption of more expensive drugs, such as, for instance, 
ciprofloxacin, imipenem/cilastatin and vancomycin re-
sulting from the assistance provided to patients in more 
critical status; general increase of antimicrobial agents 
consumption in the study period, over all in the year of 
2004; and, ultimately, constant increase in the yearly ave-
rage number of attended patients-day.
It should be emphasized, however, that the three 
latter factors, probably, explain only part of the verified 
increase in the expenditures, as the increase of average 
consumption per 100 patients-day, even if corrected by the 
increase in the volume of attendances, is lower than the ve-
rified increase of expenditures. The two main hypotheses, 
despite probable, are more difficult to verify.
Hidalgo (2003), analyzing the profile of utilization 
of 14 antimicrobial agents in the São Paulo Hospital, ob-
served significant drop in the expenses with these drugs, 
in the study period. This is due, probably, to the work de-
veloped in the institution through the program of rationa-
lization of use of antimicrobial agents, which contributed 
for the maintenance and stabilization of consumption, even 
taking into account the introduction of newer antimicro-
bial agents, with higher cost and the increase in levels of 
resistance to antimicrobial agents in the institution.
Cavalcante et al. (2005), through the elaboration 
and development of the Program of Rationalization of 
Antimicrobial Agents developed by the executor group 
of CCIH of Mário Covas State Hospital, in Santo André, 
Brazil, evaluated the prescription of antimicrobial agents 
of restrict use, between them, ceftazidime, ciprofloxacin, 
imipenem and vancomycin. Out of 503 analyzed prescrip-
tions, economy was verified in 18.8%, representing about 
R$ 68,139.52 in the costs of these drugs. 
In brief, the consumption of antimicrobial agents 
increased significantly in the institution, during the stu-
died period. It is supposed that the high consumption of 
antimicrobial agents evidenced in this study, is due to 
prescription habits, inadequacy in the adherence to norms 
of appropriate use, little experience in pharmacovigilance 
programs and the complexity of developed hospital pro-
cedures.
In this way, this study benefits not only the HUOP, 
but also other teaching institutions, in the sense to address 
policies for controlled use of antimicrobial agents, as well 
as to help the administrative sector in the budgetary previ-
sion for these medicines purchase scheduling, and mainly 
to review the control measures of hospital infection and 
the rational use of antimicrobial agents. The knowledge 
of these medicines consumption standards provides argu-
ments to improve the use rationalization of antimicrobial 
agents within the institution.
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